Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 12Gynecologic 3Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Ovarian Neoplasms 104Fallopian Tube Neoplasms 47Carcinoma, Ovarian Epithelial 27Neoplasms 12Breast Neoplasms 7Neoplasm Metastasis 5Recurrence 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Peritoneal Neoplasms 3Ovarian Cancer Recurrent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Multiple Myeloma 2Lung Neoplasms 2Disease Progression 2Colorectal Neoplasms 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1

Interventions

pembrolizumab 41Nivolumab 13Cyclophosphamide 10Carboplatin 10olaparib 7Paclitaxel 7Ipilimumab 7fludarabine 6Gemcitabine 6durvalumab 5lenvatinib 4cemiplimab 4atezolizumab 4Specimen Handling 4Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fulvestrant 4Fluorouracil 4Bevacizumab 4veliparib 3spartalizumab 3sacituzumab govitecan 3liposomal doxorubicin 3avelumab 3aldesleukin 3Taxes 3Interleukin-2 3Doxorubicin 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × liposomal doxorubicin × Gynecologic × Clear all
NCT03719326 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
35 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04244552 2023-12-29

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Atreca, Inc.

Phase 1 Terminated
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡